FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:1652-1654 October 20, 2005 Number 16 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Piccart-Gebhart, M. J. Related Article by Romond, E. H. PubMed Citation

Breast cancer is not a single disease but a group of several important tumor subtypes, each with a different natural history and each requiring a different treatment. Overexpression of HER2 (which derives its name from human epidermal growth factor receptor 2) defines one of these unique subtypes. The HER2/neu gene is a member of a family of genes encoding transmembrane receptors for growth factors, including the epidermal growth factor receptor (EGFR), HER2, HER3, and HER4. The intracellular domain of HER2 has tyrosine kinase activity that regulates important aspects of the physiology, growth, and differentiation of cells.^1,2 Extracellular domains of the . . . [Full Text of this Article]

Source Information

Dr. Burstein is an assistant professor of medicine at the Dana–Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston.

This article has been cited by other articles:

• Parton, M., Smith, I. E. (2008). Controversies in the Management of Patients With Breast Cancer: Adjuvant Endocrine Therapy in Premenopausal Women. JCO 26: 745-752 [Full Text]  
• Adriaenssens, E., Vanhecke, E., Saule, P., Mougel, A., Page, A., Romon, R., Nurcombe, V., Le Bourhis, X., Hondermarck, H. (2008). Nerve Growth Factor Is a Potential Therapeutic Target in Breast Cancer. Cancer Res. 68: 346-351 [Abstract] [Full Text]  
• Dong, L.-F., Swettenham, E., Eliasson, J., Wang, X.-F., Gold, M., Medunic, Y., Stantic, M., Low, P., Prochazka, L., Witting, P. K., Turanek, J., Akporiaye, E. T., Ralph, S. J., Neuzil, J. (2007). Vitamin E Analogues Inhibit Angiogenesis by Selective Induction of Apoptosis in Proliferating Endothelial Cells: The Role of Oxidative Stress. Cancer Res. 67: 11906-11913 [Abstract] [Full Text]  
• Kroese, M., Zimmern, R. L, Pinder, S. E (2007). HER2 status in breast cancer--an example of pharmacogenetic testing. JRSM 100: 326-329 [Abstract] [Full Text]  
• Karantza-Wadsworth, V., Patel, S., Kravchuk, O., Chen, G., Mathew, R., Jin, S., White, E. (2007). Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis. Genes Dev. 21: 1621-1635 [Abstract] [Full Text]  
• Anderson, W. F., Matsuno, R. (2006). Breast cancer heterogeneity: a mixture of at least two main types?. JNCI J Natl Cancer Inst 98: 948-951 [Full Text]  
• Helguera, G., Rodriguez, J. A., Penichet, M. L. (2006). Cytokines fused to antibodies and their combinations as therapeutic agents against different peritoneal HER2/neu expressing tumors.. Molecular Cancer Therapeutics 5: 1029-1040 [Abstract] [Full Text]  
• (2005). Trastuzumab for HER2-Positive Breast Cancer: A Major Step Forward. JWatch Women's Health 2005: 1-1 [Full Text]